TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in Nature Medicine links lower levels of the protective protein NRF2 in oligodendrocytes to abnormal myelin, loss of large nerve fibers and faster cognitive decline. Human tissue findings show an association, while mouse experiments provide evidence of a possible causal role. The work points to a pathway targeted by existing drugs, but does not establish a treatment for age-related decline.
Researchers from the University of Edinburgh and the UK Dementia Research Institute report that age-related changes in oligodendrocytes, cells that maintain the insulating coating around nerve fibers, may contribute to faster cognitive decline. The study, published in Nature Medicine, links lower levels of the protective protein NRF2 in these cells with abnormal myelin and damage to nerve fibers, and uses mouse experiments to investigate a possible causal connection.
The team studied participants in the Lothian Birth Cohort 1936, whose cognitive abilities had been followed from childhood into older age. Of 1,091 people enrolled, 866 completed additional assessments after age 70. Researchers measured memory, information-processing speed and spatial reasoning between ages 70 and 82. Most participants experienced some decline, but the pace differed substantially.
In brain tissue collected after death from a subset of participants, greater decline over time was associated with fewer large nerve fibers and an abnormal accumulation of myelin. Myelin normally helps nerve signals travel efficiently. The tissue findings were associated with the rate of cognitive change, rather than a person’s performance on a test at one particular age.
The researchers also found lower levels of NRF2 in oligodendrocytes among people with more severe decline. In mice, reducing NRF2 specifically in these cells led to excessive myelin, loss of large nerve fibers and weaker gains in cognitive performance as the animals aged. The experiments support a role for NRF2 in oligodendrocyte function, though findings in mice do not establish that the same mechanism causes human cognitive decline.
A New Target in Brain Aging
The findings may shift research attention toward cells that support nerve fibers, not just the fibers themselves. If further studies confirm that oligodendrocyte dysfunction contributes to decline, protecting these cells or restoring their normal activity could offer a route to preserving brain function as people age.
The study also identifies the NRF2 pathway as a possible therapeutic target. Drugs that act on this pathway are already used for other neurological conditions, including multiple sclerosis. That makes repurposing an area for future research, not a treatment recommendation: the study does not show that these drugs prevent or reverse age-related cognitive decline.
Products Worth Considering
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Oura Ring 5 Smart Ring – Stealth, Size 11
As an affiliate, we earn on qualifying purchases.
Decades of Cognitive Tracking
The Lothian cohort is useful for this question because researchers could compare brain tissue findings with cognitive changes measured over many years, rather than relying only on a single test taken late in life. This allowed the team to examine whether particular tissue features corresponded to faster or slower change.
Oligodendrocytes produce and maintain myelin, a sheath around nerve fibers. The study challenges the assumption that these cells are consistently protective: it suggests that, under some aging-related conditions, their dysfunction may coincide with abnormal myelin and fiber loss. The human tissue analysis shows an association; the mouse work tests the mechanism under experimental conditions.
“As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.”
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
Human Cause Still Unproven
The human findings come from brain tissue examined after participants’ deaths and show an association between NRF2 levels, myelin abnormalities and the pace of decline. They cannot establish on their own that changes in oligodendrocytes caused participants’ cognitive changes. The mouse experiments provide evidence about a possible mechanism but cannot confirm that it operates in the same way in people.
The report does not establish whether an NRF2-targeting drug would be safe or effective for older adults with age-related decline, which patients might benefit, or when treatment would need to begin. It also does not show that abnormal myelin is the sole explanation for cognitive decline, which can have multiple contributing factors.
Testing the Pathway in People
Further research will need to establish whether increasing NRF2 activity can protect oligodendrocytes and nerve fibers in aging, and whether any benefit translates to measurable cognitive outcomes in people. That would require studies designed to test dose, safety and effectiveness in the relevant population, rather than assuming results from multiple sclerosis or mice apply to age-related decline.
For now, the study offers a potential biological target, not a proven therapy. The next key milestone is evidence from human research showing whether interventions affecting this pathway can slow cognitive decline and which older adults, if any, could benefit.
Key Questions
What brain cells did the study examine?
It examined oligodendrocytes, cells that produce and maintain myelin, the insulating coating around nerve fibers.
What is NRF2?
NRF2 is a protein that regulates genes involved in cellular protection and normal function. The study found lower NRF2 levels in oligodendrocytes in people with more severe cognitive decline.
Does the study prove these cells cause cognitive decline in people?
No. The human tissue results show an association. Mouse experiments support a possible mechanism, but they do not prove the same cause-and-effect relationship in humans.
Could existing drugs treat age-related cognitive decline?
The researchers say the NRF2 pathway is targeted by drugs used for other conditions, including multiple sclerosis. This study does not show that those drugs treat age-related cognitive decline; that possibility needs to be tested.
Source: rss
